Effects of 12 weeks of tadalafil treatment on ejaculatory and orgasmic dysfunction and sexual satisfaction in patients with mild to severe erectile dysfunction: integrated analysis of 17 placebo-controlled studies

摘要: What's known on the subject? and What does study add? Disorders of ejaculation orgasm are common, even in men with only mild erectile dysfunction (ED). Treatment phosphodiesterase type-5 inhibitor tadalafil was associated improvements ejaculatory orgasmic function. Patients residual or experience reduced sexual satisfaction. These findings need to be corroborated further clinical trials involving without ED. Objectives To compare effects function patients presenting (ED). To determine post-treatment (EjD) (OD) measures satisfaction. Patients Methods Data from 17 placebo-controlled 12-week (5, 10, 20 mg) as needed ED were integrated. EjD OD severities defined by patient responses International Index Erectile Function, question 9 (IIEF-Q9; ejaculation) IIEF-Q10 (orgasm), respectively. Satisfaction evaluated using intercourse overall satisfaction domains IIEF Sexual Encounter Profile 5. Analyses covariance performed mean function, chi-squared tests differences endpoint IIEF-Q9 IIEF-Q10. Results A total 3581 randomized subjects studied. Treatment 10 20 mg significant increases (vs placebo) across all baseline ED, EjD, severity strata. In group, 66% severe EjD reported improved compared 36% placebo group (P < 0.001). Similarly, tadalafil-treated 35% for placebo; P 0.001) improvement. Residual after treatment had negative impacts satisfaction. Limitations analysis include its retrospective nature use an instrument (IIEF) yet unknown performance measuring OD. Conclusions Tadalafil satisfaction. Proportions reporting ≈ twofold higher than placebo. These warrant corroboration prospective (without ED).